Head to Head Review: LadRx (OTCMKTS:CYTR) vs. MeiraGTx (NASDAQ:MGTX)

LadRx (OTCMKTS:CYTR) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.

Analyst Ratings

This is a breakdown of recent ratings and price targets for LadRx and MeiraGTx, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LadRx	0	0	0	0	N/A
MeiraGTx	0	0	2	0	3.00

MeiraGTx has a consensus price target of $22.50, indicating a potential upside of 426.93%. Given MeiraGTx’s higher probable upside, analysts clearly believe MeiraGTx is more favorable than LadRx.

Volatility & Risk

LadRx has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of LadRx shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 12.8% of LadRx shares are held by insiders. Comparatively, 8.4% of MeiraGTx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares LadRx and MeiraGTx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LadRx	N/A	-67.61%	-45.39%
MeiraGTx	-1,146.81%	-152.82%	-56.41%

Valuation & Earnings

This table compares LadRx and MeiraGTx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LadRx	N/A	N/A	-$6.70 million	($0.15)	-0.61
MeiraGTx	$8.12 million	33.81	-$84.03 million	($1.17)	-3.65

LadRx has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Summary

LadRx beats MeiraGTx on 8 of the 12 factors compared between the two stocks.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.